SCHEMBL6630951

SCHEMBL6630951

COc1ccc2c(c1)C=CC1(O2)N(C)c2ccc(N3C(=O)CCC3=O)cc2C1(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.50
GAA P10253 6/20 0.50
KMT2A Q03164 5/20 0.50
LMNA P02545 5/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
MEN1 O00255 4/20 0.50
RECQL P46063 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
THRB P10828 3/20 0.50
PLIN1 O60240 1/20 0.50
PKM P14618 1/20 0.50
TSHR P16473 1/20 0.50
PLIN5 Q00G26 1/20 0.50
ABHD5 Q8WTS1 1/20 0.50
GFER P55789 1/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ALPG P10696 1/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6628826 0.93 MAPT (0.42) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6630398 0.89 MEN1 (0.45) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6628794 0.87 MEN1 (0.49) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6629307 0.87 MEN1 (0.48) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6632591 0.87 MAPT (0.64) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6629971 0.87 KMT2A (0.48) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6628970 0.85 MEN1 (0.64) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6630260 0.85 MEN1 (0.47) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL6627625 0.83 MEN1 (0.36) MAPTGAAKMT2ALMNASMN1; SMN2
SCHEMBL8681722 0.81 MAPT (0.56) MAPTGAAKMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299391-B1 INDOLINOSPIROPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE JOHNSON & JOHNSON VISION CARE (US) 2004-12-29 EP disclosed
US-6803471-B2 USEFUL AS PHOTOCHROMIC COMPOUNDS; COVALENTLY ATTACHED TO WANG RESINS AND METHOD OF ATTACHING; OPHTHALMIC LENSES JOHNSON & JOHNSON VISION CARE, INC. 2004-10-12 US disclosed
US-6521753-B1 Indolinospiropyran compounds and methods for their manufacture JOHNSON & JOHNSON VISION CARE, INC. 2003-02-18 US disclosed
US-20020087010-A1 Indolinospiropyran compounds and methods for their manufacture ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020087010-A1 Indolinospiropyran compounds and methods for their manufacture DHPS, IDO1, INMT MAPT 537/4885GAA 3983/4885KMT2A 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.